iRhythm Technologies, Inc.

iRhythm Technologies, Inc.

IRTC
iRhythm Technologies, Inc.US flagNASDAQ Global Select
125.69
USD
+2.53
- -
4.13BMarket Cap
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.47
2.45
12.12
4.38
6.17
8.49
9.55
11.01
13.74
16.14
18.97
23.35
25.43
Basic EPS, GAAP
-1.07
-1.54
-3.95
-1.31
-2.11
-2.16
-1.58
-3.46
-3.88
-4.04
-3.63
-1.39
-0.43
Free Cash Flow per Basic Share
-1.09
-1.34
-3.67
-0.82
-1.43
-1.67
-0.98
-2.24
-1.77
-2.97
-1.46
1.08
1.2
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-3.99
-5.04
4.18
3.4
2.14
5.07
11.77
9.48
7.94
6.79
2.9
4.73
5.66
Tangible Book Value per Share
-4.03
-5.08
4.14
3.37
2.1
5.04
11.74
9.45
7.91
6.76
2.87
4.7
5.63
Basic Weighted Avg Shares
15
15
5
23
24
25
28
29
30
31
31
32
32
Sales/Revenue/Turnover
22
36
64
99
147
215
265
323
411
493
592
747
825
Operating Margin (%)
-67.89
-59.85
-24.32
-27.83
-31.02
-25.52
-16.47
-30.96
-21.21
-23.16
-19.41
-7.09
-1.08
Depreciation Expense
- -
- -
1
2
2
3
13
17
20
22
26
26
27
Net Income, GAAP
-16
-23
-21
-30
-50
-55
-44
-101
-116
-123
-113
-45
-14
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
7.42
Profit Margin (%)
-72.79
-63.09
-32.62
-30
-34.21
-25.43
-16.53
-31.4
-28.27
-25.05
-19.14
-5.96
-1.69
Working Capital
11
24
105
99
74
121
312
218
200
123
535
551
560
LT Debt
6
31
32
32
35
119
103
95
118
115
721
714
710
Total Equity
-81
-102
93
80
52
135
342
280
240
210
91
153
186
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-0.53
Return on Common Equity (%)
- -
- -
- -
-34.56
-76.51
-58.19
-18.38
-32.64
-44.73
-54.86
-75.27
-36.57
-9.63

Capital Structure

FRC

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
17
17
62
LT Borrowings
650
650
651
LT Finance Leases
65
62
59
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
32
33
33
Market Capitalization
5,731
3,877
3,908

Working Capital

FRC

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
703
681
756
Cash, Cash Equivalents & STI
584
550
591
Accounts Receivable, Net
76
81
84
Inventories
22
24
23
Total Current Liabilities
152
132
196
Payables & Accruals
130
108
129
ST Debt
17
17
62
Deferred Revenue
4
4
4

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
3.89%
-6.7%
68.02%
Free Cash Flow
3.39%
-6.57%
-175.78%
Net Income, GAAP
17.52%
16.65%
-60.67%
Sales/Revenue/Turnover
36.52%
23.06%
26.24%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
132
148
148
164
592
2025
159
187
193
209
747
2026
199
224
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-1.47
-0.65
-1.48
-0.04
-3.63
2025
-0.97
-0.44
-0.16
0.17
-1.39
2026
-0.43
-0.01
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Quentin S. Blackford
Full Time Employees
2,400
Sector
Healthcare
Industry
Medical - Devices
Address
699 8th Street San Francisco CA United States of America 94103
IPO Date
Oct 20, 2016
Business
iRhythm Technologies, Inc. iRhythm Technologies, Inc. (IRTC) is a leading digital healthcare company that develops and commercializes wearable biosensors and cloud-based platforms focused on cardiac arrhythmia detection and prediction. The company offers a comprehensive suite of ambulatory cardiac monitoring solutions through its Zio platform, including the Zio monitor for long-term continuous ECG monitoring up to 14 days, Zio XT for extended wear applications, Zio AT for real-time event monitoring without battery changes, and the recently submitted Zio MCT next-generation mobile cardiac telemetry device featuring a smaller form factor, 21-day wear period, and advanced detection algorithms; these services integrate AI-powered analytics verified by qualified cardiac technicians, patient symptom logging via the MyZio mobile app, and ZioSuite data management for physicians, achieving high diagnostic yield, 99% physician agreement on reports, and superior clinical outcomes compared to shorter-duration monitors. iRhythm Technologies, Inc. primarily serves cardiologists, primary care providers, and health systems in the United States, with expanding operations in Europe, the United Kingdom, Japan, and the Philippines from its headquarters at 699 8th Street, Suite 600, San Francisco, California, where it was founded in 2006. In recent developments, the company formed a strategic AI partnership with Lucem Health to enable early arrhythmia detection in high-risk populations such as those with type 2 diabetes, chronic kidney disease, COPD, and coronary artery disease; launched Zio long-term continuous monitoring services in Japan; reported record Q3 2025 revenue of $192.9 million, up 30.7% year-over-year, with raised full-year guidance to $735-740 million; published significant real-world studies in Heart Rhythm validating Zio performance and presented findings at AHA Scientific Sessions 2025 and other conferences demonstrating advantages in arrhythmia yield and healthcare cost reduction; and submitted a 510(k) filing to the FDA for Zio MCT while expanding value-based care partnerships across 18 active accounts.

Company News

APIChatGPT
  • iRhythm to Acquire VitalConnect to Expand Cardiac Monitoring Platform

  • Here's Why iRhythm Holdings, Inc. (IRTC) is a Strong Momentum Stock

  • iRhythm Technologies $IRTC Shares Sold by Bank of America Corp DE

  • iRhythm Q2 Earnings Beat Estimates on Volume Growth, '26 View Raised

  • Kuehn Law Encourages Investors of iRhythm Technologies, Inc. to Contact Law Firm

  • Kuehn Law Encourages Investors of iRhythm Technologies, Inc. to Contact Law Firm

  • iRhythm Combines Strong Performance with VitalConnect Buy to Expand Remote Cardiac Care

  • iRhythm Holdings, Inc. (IRTC) Q2 2026 Earnings Call Transcript

  • iRhythm Holdings, Inc. (IRTC) Tops Q2 Earnings and Revenue Estimates

  • iRhythm Technologies Q2 Earnings Call Highlights

  • iRhythm Holdings Announces Second Quarter 2026 Financial Results

  • Bernstein Litowitz Berger & Grossmann LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of iRhythm Technologies, Inc. Common Stock

  • Did iRhythm Technologies, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

  • Did iRhythm Technologies, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

  • Kuehn Law Encourages Investors of iRhythm Technologies, Inc. to Contact Law Firm

  • Castleark Management LLC Sells 23,000 Shares of iRhythm Technologies $IRTC

  • iRhythm Technologies $IRTC Shares Sold by Bessemer Group Inc.

  • iRhythm Holdings to Report Second Quarter 2026 Financial Results on August 6, 2026

  • Did iRhythm Technologies, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

  • Kuehn Law Encourages Investors of iRhythm Technologies, Inc. to Contact Law Firm